Immunotherapy最新文献_第6页

Part A of the LILAC study of litifilimab for systemic lupus erythematosus: a plain language summary. 利非利单抗治疗系统性红斑狼疮的LILAC研究的A部分：简单的语言总结。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-24 DOI: 10.1080/1750743X.2025.2459054

Richard A Furie, Ronald F van Vollenhoven, Kenneth Kalunian, Sandra Navarra, Juanita Romero-Diaz, Victoria Werth, Xiaobi Huang, Hua Carroll, Adam Meyers, Cristina Musselli, Nathalie Franchimont, Catherine Barbey

引用次数: 0

Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publication. Benralizumab在严重嗜酸性粒细胞哮喘中的生物学应用和关键临床亚组：真实世界的XALOC-1项目：发表的简明语言摘要

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-11 DOI: 10.1080/1750743X.2025.2457931

David J Jackson, Girolamo Pelaia, Benjamin Emmanuel, Trung N Tran, David Cohen, Vivian H Shih, Anat Shavit, Douglas Arbetter, Rohit Katial, Adrian Paul J Rabe, Esther Garcia Gil, Marisa Pardal, Javier Nuevo, Michael Watt, Silvia Boarino, Sheena Kayaniyil, Claudia Chaves Loureiro, Alicia Padilla-Galo

引用次数: 0

From natural defenders to therapeutic warriors: NK cells in HIV immunotherapy. 从天然卫士到治疗勇士：艾滋病免疫疗法中的 NK 细胞。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-05 DOI: 10.1080/1750743X.2025.2460965

Thessa Laeremans, Amber Janssens, Joeri L Aerts

{"title":"From natural defenders to therapeutic warriors: NK cells in HIV immunotherapy.","authors":"Thessa Laeremans, Amber Janssens, Joeri L Aerts","doi":"10.1080/1750743X.2025.2460965","DOIUrl":"10.1080/1750743X.2025.2460965","url":null,"abstract":"Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells both play essential roles in controlling viral infections by eliminating virus-infected cells. Unlike CTLs, which require priming and activation by antigen-presenting cells, NK cells possess a remarkable capacity to mount a rapid antiviral immune response immediately after infection. Additionally, they can bolster the adaptive immune system by secreting cytokines and directly interacting with other immune cells. However, during chronic human immunodeficiency virus (HIV) infection, various immune cells, including NK cells, experience functional impairments. This has led to the exploration of NK cell-based immunotherapy as a promising strategy to reverse these dysfunctions and contribute to the pursuit of a functional cure for HIV. Building on the success of NK cell therapies in cancer treatment, these approaches offer significant potential for transforming the HIV cure field. This review provides a comprehensive overview of the latest advances in NK cell-based immunotherapy for HIV, outlining the progress made and the key challenges that must be overcome to achieve a functional cure for people living with HIV.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"133-145"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11901454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis. ROCKET：一项评估rocatinlimab治疗中重度特应性皮炎疗效和安全性的iii期项目。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-26 DOI: 10.1080/1750743X.2025.2464528

Emma Guttman-Yassky, Eric Simpson, Robert Bissonnette, Lawrence F Eichenfield, Kenji Kabashima, Paula C Luna, Janá Tresnak Hercogová, Lynda Spelman, Margitta Worm, Ehsanollah Esfandiari, Takahiro Arai, Hirotaka Mano, Prista Charuworn, Andrea Wang, Gregory Kricorian

{"title":"ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis.","authors":"Emma Guttman-Yassky, Eric Simpson, Robert Bissonnette, Lawrence F Eichenfield, Kenji Kabashima, Paula C Luna, Janá Tresnak Hercogová, Lynda Spelman, Margitta Worm, Ehsanollah Esfandiari, Takahiro Arai, Hirotaka Mano, Prista Charuworn, Andrea Wang, Gregory Kricorian","doi":"10.1080/1750743X.2025.2464528","DOIUrl":"10.1080/1750743X.2025.2464528","url":null,"abstract":"Atopic dermatitis (AD) is a chronic inflammatory disease affecting ~ 10% of adults and ~ 20% of children globally. Many patients with moderate-to-severe AD receiving systemic therapies, including biologics and Janus kinase (JAK) inhibitors, fail to reach or maintain treatment goals due to lack of durable response or safety/tolerability issues. Rocatinlimab is a T-cell rebalancing therapy that inhibits and reduces pathogenic T cells by targeting the OX40 receptor. ROCKET, a large, global phase 3 program of eight clinical trials (NCT05398445; NCT05651711; NCT05724199; NCT05899816; NCT05704738; NCT05633355; NCT05882877; NCT06224192), will evaluate the efficacy, durability of response, and long-term safety of rocatinlimab as monotherapy and combination therapy in adult and adolescent patients with moderate-to-severe AD with or without prior exposure to biologics or systemic JAK inhibitors.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"83-94"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11901500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapies for prevention and treatment of type 1 diabetes. 预防和治疗1型糖尿病的免疫疗法。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-03-04 DOI: 10.1080/1750743X.2025.2473311

Rebecca Jeun

引用次数: 0

Extended survival of a patient with gastrointestinal multiple malignancies managed with anti-PD-1 immunotherapy: a case report. 抗pd -1免疫治疗延长胃肠道多发性恶性肿瘤患者的生存期：1例报告。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-02-01 Epub Date: 2025-02-11 DOI: 10.1080/1750743X.2025.2463309

Tianhao Guo, Yifan Hui, Wenjian Zhu, Fei Ke, Tingting Zhou, Wenli Qiu, Xuan Li, Liu Li, Haibo Cheng

{"title":"Extended survival of a patient with gastrointestinal multiple malignancies managed with anti-PD-1 immunotherapy: a case report.","authors":"Tianhao Guo, Yifan Hui, Wenjian Zhu, Fei Ke, Tingting Zhou, Wenli Qiu, Xuan Li, Liu Li, Haibo Cheng","doi":"10.1080/1750743X.2025.2463309","DOIUrl":"10.1080/1750743X.2025.2463309","url":null,"abstract":"Introduction: The annual rise in gastrointestinal cancer cases is evident, yet the occurrence of multiple primary malignancies remains comparatively uncommon. In recent years, immunotherapy has swiftly emerged as the leading treatment for several solid tumors, including gastrointestinal cancers. Single treatments might be ineffective, necessitating the need for comprehensive integrative medicine.Case description: This study reports a case of multiple cancers, including colorectal and gastric cancers. Diverse systemic treatments, like capecitabine, the combination of capecitabine and paclitaxel liposome, as well as capecitabine with toripalimab, were unsuccessful. Nevertheless, prolonged survival was attained through anti-PD-1 immunotherapy complemented by alternative medicine approaches. The patient has exceeded a 35-month survival post-initial diagnosis and 20-month survival since the subsequent diagnosis, markedly surpassing the prognosis often associated with advanced-stage multiple cancers.Conclusion: In summary, this case underscores the potential effectiveness of a holistic, integrative medical approach in managing advanced multiple malignancies amid drug resistance and disease progression.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"95-101"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11901419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pegcetacoplan for the treatment of geographic atrophy due to age-related macular degeneration: a plain language summary of OAKS and DERBY clinical studies. Pegcetacoplan用于治疗因年龄相关性黄斑变性引起的地理萎缩：OAKS和DERBY临床研究的简单语言总结。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-01-17 DOI: 10.1080/1750743X.2025.2449760

Jeffrey S Heier, Eleonora M Lad, Frank G Holz, Philip J Rosenfeld, Robyn H Guymer, David Boyer, Federico Grossi, Caroline R Baumal, Jean-Francois Korobelnik, Jason S Slakter, Nadia K Waheed, Ravi Metlapally, Ian Pearce, Nathan Steinle, Anibal A Francone, Allen Hu, David R Lally, Pascal Deschatelets, Cedric Francois, Caleb Bliss, Giovanni Staurenghi, Jordi Monés, Rishi P Singh, Ramiro Ribeiro, Charles C Wykoff

引用次数: 0

Disparities in utilization of novel cancer therapies in advanced stage III and IV melanoma and variance in outcomes. 在晚期III期和IV期黑色素瘤中使用新型癌症疗法的差异和结果的差异。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-01-01 Epub Date: 2025-01-18 DOI: 10.1080/1750743X.2025.2452836

Mohammad S Ali, Jae Ahn, N Joseph Espat, Abdul S Calvino, James Koness, Ponnandai Somasundar, Steve Kwon

{"title":"Disparities in utilization of novel cancer therapies in advanced stage III and IV melanoma and variance in outcomes.","authors":"Mohammad S Ali, Jae Ahn, N Joseph Espat, Abdul S Calvino, James Koness, Ponnandai Somasundar, Steve Kwon","doi":"10.1080/1750743X.2025.2452836","DOIUrl":"10.1080/1750743X.2025.2452836","url":null,"abstract":"Introduction: Significant gains in advanced melanoma have been made through immunotherapy trials. Factors influencing equitable access and survival impact of these novel therapies are not well-defined.Method: Retrospective analysis using National Cancer Database of patients with advanced stage III and IV melanoma from 2004 to 2021. Multivariable logistic regression was used to study the use of immunotherapy and Cox proportional hazard regression to evaluate overall survival (OS).Results: 47,427 patients with increasing utilization of immunotherapy from 13.78% in 2004 to 65.88% by 2021. Inequitable adoption were impacted by age, sex, socioeconomic status/affordability, insurance types and residential educational/income level. Receiving immunotherapy was associated with a 44% improvement in OS (HR 0.56, 95% CI 0.54-0.57) and receiving a clinical trial-based therapy was associated with a 37% improvement (HR 0.63, 95% CI 0.53-0.75). Among patients who received immunotherapy or clinical trial-base therapy, there was 40% worse survival in non-Hispanic Black patients (HR 1.40, 95% CI 1.16-1.69) compared to non-Hispanic Whites.Conclusion: There are disparities in utilization of immunotherapy that is influenced by socioeconomic status. Race and ethnicity had a significant influence in differential impact on survival outcomes of immunotherapies highlighting the importance of increasing underrepresented population participation in trials that lead to novel therapies.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"37-46"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Survival impact of immune-related adverse events in extensive stage small cell lung cancer patients: a retrospective cohort study. 广泛期小细胞肺癌患者免疫相关不良事件对生存的影响：一项回顾性队列研究

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-01-01 Epub Date: 2025-01-23 DOI: 10.1080/1750743X.2025.2456448

John C Hunting, Sarah N Price, Andrew T Faucheux, Eric Olson, Catherine A Elko, Alexander Quattlebaum, Jimmy Ruiz, Thomas William Lycan

{"title":"Survival impact of immune-related adverse events in extensive stage small cell lung cancer patients: a retrospective cohort study.","authors":"John C Hunting, Sarah N Price, Andrew T Faucheux, Eric Olson, Catherine A Elko, Alexander Quattlebaum, Jimmy Ruiz, Thomas William Lycan","doi":"10.1080/1750743X.2025.2456448","DOIUrl":"10.1080/1750743X.2025.2456448","url":null,"abstract":"Background: Prior research indicates a connection between immune-related adverse events (irAEs) and improved progression-free survival (PFS) and overall survival (OS) in non-small cell lung cancer. However, limited data exists for extensive stage small cell lung cancer (ES-SCLC).Methods: This study included all ES-SCLC patients who received at least one dose of an immune checkpoint inhibitor between 2 January 2011 and 4 July 2022 using a large retrospective registry from a single institution. PFS and OS were right-censored at the date of last follow-up and were estimated using the Kaplan-Meier method. Differences in PFS and OS between irAE groups were assessed using Cox proportional hazards models.Results: Among 245 patients with ES-SCLC; 56 (23%) experienced irAEs, 24 (42.9%) of which were high-grade (3-4). High-grade irAEs occurred at a median of 1.2 months (interquartile range [IQR] 0.45-2.5), while low-grade irAE occurred at 2.8 months (1.3-5.2). PFS was significantly longer among any irAE vs none (HR = 0.49; [95%CI 0.32-0.77]) as was OS (HR = 0.49; [95%CI 0.34-0.72]).Conclusions: In ES-SCLC patients treated with immunotherapy, those who experienced any irAE demonstrated a two-fold increase in both PFS and OS compared to those without an irAE. This is consistent with other tumor primaries.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"19-24"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the role of immunotherapy in the management of follicular cell-derived thyroid cancer. 探讨免疫治疗在滤泡细胞源性甲状腺癌治疗中的作用。

IF 2.7 4区医学

Immunotherapy Pub Date : 2025-01-01 Epub Date: 2025-02-03 DOI: 10.1080/1750743X.2025.2455922

Paige Benson, Omar Abdel-Rahman

引用次数: 0